FDA Inspection 1016395 — Cantrell Drug Company

Cantrell Drug Company — FEI 3004483441

The FDA completed an inspection of Cantrell Drug Company on June 29, 2017 in Little Rock, AR. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 8 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
June 29, 2017
Fiscal Year
2017
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Little Rock, AR (United States)

Citations

IDCFRDescription
103321 CFR 211.22(a)Authority lacking to review records, investigate errors
110521 CFR 211.22(d)Procedures not in writing, fully followed
143321 CFR 211.42(c)(10)(iii)Air Supply
143521 CFR 211.42(c)(10)(v)Cleaning System
145121 CFR 211.113(b)Procedures for sterile drug products
18008FDCA 503B(a)(10)Drug product label, outsourcer facility
191421 CFR 211.166(a)Lack of written stability program
202721 CFR 211.192Investigations of discrepancies, failures